Core Scientific shareholders reject $9 billion CoreWeave offer, deal terminated

Core Scientific (CORZ.O) shareholders rejected an all-stock, $9 billion acquisition offer from CoreWeave (CRWV.O), marking the second failed attempt by CoreWeave to acquire the crypto miner. Major shareholders and proxy advisors opposed the deal, citing concerns over valuation and deal structure, believing Core Scientific holds greater standalone value, potentially influenced by high AI-related valuations. Despite the board's recommendation, the rejection led to a marginal rise in Core Scientific shares, while CoreWeave's stock declined 3.9%.

Analysis

Core Scientific (CORZ.O) shareholders have rejected CoreWeave's (CRWV.O) $9 billion all-stock acquisition offer, marking the second failed attempt by CoreWeave to acquire the crypto miner. This decision, despite Core Scientific's board recommendation, resulted in a marginal uptick for CORZ shares and a 3.9% decline for CRWV. The proposed deal, valued at $9 billion, aimed to secure essential energy and data center capacity for CoreWeave.

The rejection was driven by significant shareholder opposition, including from Two Seas Capital, the largest active shareholder, and proxy advisory firm Institutional Shareholder Services. Concerns centered on the deal's structure, specifically the fixed exchange ratio which exposed CORZ shareholders to CRWV share price volatility, and a perceived undervaluation of Core Scientific's standalone potential. ISS explicitly recommended against the deal, citing Core Scientific's considerable success as an independent entity.

Analysts suggest the vote was influenced by the elevated valuations of AI-related companies, leading shareholders to believe Core Scientific's value should be higher. This sentiment, described by D.A. Davidson analyst Gil Luria as "AI trade froth," raises questions about current market valuations and the perceived intrinsic value of assets with AI infrastructure relevance. CoreWeave's CEO acknowledged the decision, indicating a continued commercial partnership.

Key Decisions for Investors

• Monitor Core Scientific's strategic execution and standalone financial performance, particularly its ability to capitalize on its perceived intrinsic value in the current market.
• Evaluate CoreWeave's revised strategy for securing critical data center and energy capacity, as this setback may impact its growth trajectory and competitive positioning.
• Assess the broader market implications of "AI trade froth" on valuations, especially for companies with exposure to AI infrastructure, and consider potential overvaluation risks.